Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al
- PMID: 32816700
- DOI: 10.1136/annrheumdis-2020-218788
Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al
Keywords: biological therapy; epidemiology; glucocorticoids.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.Ann Rheum Dis. 2020 Sep;79(9):1143-1151. doi: 10.1136/annrheumdis-2020-218479. Epub 2020 Jul 20. Ann Rheum Dis. 2020. PMID: 32719045 Free PMC article. Clinical Trial.
-
High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab.Ann Rheum Dis. 2022 Oct;81(10):e202. doi: 10.1136/annrheumdis-2020-218761. Epub 2020 Aug 19. Ann Rheum Dis. 2022. PMID: 32816701 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
